Medication info
Lozatine Plus Tablet

Lozatine Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607957 · Notified 2006.10.16 · Insurance code 647300260

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medication is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medication may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medication when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Combination therapy with individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medication. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. For patients with more severe renal impairment, loop diuretics are preferable to thiazide drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medication cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dosage adjustment.
Child dose
○ Pediatric patients (under 18 years) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used to effectively lower and manage the blood pressure of hypertension patients whose blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medication is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medication may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medication when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Combination therapy with individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medication. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. For patients with more severe renal impairment, loop diuretics are preferable to thiazide drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medication cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dosage adjustment.

Child dose

○ Pediatric patients (under 18 years) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to patients with certain diseases or conditions, such as those with severely impaired kidney function, severe liver impairment, or allergies, as it may pose risks. Patients with low blood pressure or electrolyte imbalances, those with gout or hyperuricemia, and the elderly require special caution when using this medication. While taking this medication, regular blood tests to monitor electrolytes and kidney function should be conducted, paying particular attention to ensure potassium levels do not become too high or too low. This medication may cause side effects such as dizziness, cough, skin rash, muscle pain, and dyspepsia, and in severe cases, serious reactions such as angioedema or cardiac arrhythmias may occur, so patients should consult a doctor immediately if any unusual symptoms arise. Additionally, this medication may interact with certain drugs, so it is essential to inform the doctor or pharmacist if other medications are being taken. Containing hydrochlorothiazide, this medication may increase skin sensitivity to sunlight, so it is recommended to avoid sun exposure and use sunscreen as needed. There is a possibility of dizziness or drowsiness while driving or operating machinery, so caution is advised, especially during the initial stages of treatment or when doses are changed. This medication is not to be used in children, and breastfeeding women should either discontinue breastfeeding or stop using this medication. Finally, this medication should be stored out of reach of children and kept sealed in its original container for safety.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuralgia
  • panic disorder
  • sensory disturbances
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequency of urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastric irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle twitching
  • agitation
  • renal failure
  • renal impairment
  • interstitial nephritis
  • sicca syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylaxis
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in an opaque container. Additionally, to safeguard the medication, it is best to store it at room temperature, that is, between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.